Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix Inc (PULM) is a clinical-stage biopharmaceutical company pioneering inhaled therapeutics through its proprietary iSPERSE™ dry powder delivery platform. This resource provides investors and industry stakeholders with comprehensive updates on the company's progress in developing treatments for respiratory diseases and central nervous system disorders.
Our curated news collection offers timely access to clinical trial developments, regulatory milestones, and strategic partnerships critical for evaluating PULM's growth trajectory. Track updates spanning pulmonary infection therapies, migraine treatment candidates, and technology licensing agreements that demonstrate the versatility of the iSPERSE platform.
Key content categories include progress reports on lead drug candidates, intellectual property expansions, and collaborative research initiatives. This centralized hub eliminates the need to monitor multiple sources, providing verified updates directly from corporate communications and validated industry reports.
Bookmark this page for efficient monitoring of Pulmatrix's advancements in engineered dry powder formulations and therapeutic applications. Regular visits ensure you maintain current awareness of material events influencing the company's position in the competitive inhaled therapeutics market.
Pulmatrix, Inc. (NASDAQ: PULM) announced its 2022 financial results and corporate updates on March 30, 2023. The company reported revenue of $6.1 million, a 17% increase from $5.2 million in 2021, driven by collaborations. The year-end cash position stood at $35.6 million, providing a runway into Q2 2024. Significant milestones include the initiation of a Phase 2b study for PUR1900, with the first patient dosed in Q1 2023, and successful topline results for the Phase 1 study of PUR3100, showing promising safety and efficacy data. The company aims for further clinical studies for both PUR1900 and PUR3100.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first patient in a Phase 2b clinical trial for PUR1900, an inhaled treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. This double-blind, placebo-controlled study will assess the safety and efficacy of PUR1900 over 16 weeks, followed by an 8-week observation period. The trial aims to enroll 30 subjects across the U.S., U.K., Australia, and France. This milestone supports Pulmatrix's collaboration with Cipla and targets proof-of-concept data by mid-2024, potentially establishing PUR1900 as the first approved treatment for ABPA.
FAQ
What is the current stock price of Pulmatrix (PULM)?
What is the market cap of Pulmatrix (PULM)?
